Duvelisib is a targeted therapy known as a kinase inhibitor. It works by blocking specific proteins in cells called PI3K-δ and PI3K-γ, which are involved in the growth and survival of certain blood cancer cells, including those in follicular lymphoma and other B-cell malignancies. By inhibiting these proteins, duvelisib disrupts important cell signaling pathways that cancer cells use to grow, divide, and migrate. This can slow down or stop the progression of the disease.

Duvelisib also affects the immune environment around the cancer by reducing the movement of certain immune cells and decreasing signals that help cancer cells survive. This dual action helps to control the spread of cancer and can lead to a reduction in tumor size or a delay in disease progression.

duvelisib

Common brand names

Approved use in